RECENT NEWS

Rapid diagnostic firm OCEAN Dx has announced the successful completion of a clinical evaluation study for its innovative rapid diagnostic test for sepsis, which shows it achieved results consistent with the gold standard for sepsis detection.

National surveillance data published by the UK Health Security Agency (UKHSA) show that the total number of antibiotic-resistant infections in 2024 equates to an average of nearly 400 newly reported cases per week.

Lunit, a provider of AI for cancer diagnostics and precision oncology, and laboratory services firm Labcorp, have announced a collaborative initiative to accelerate innovation in digital pathology and artificial intelligence for oncology research and clinical care.

IBMS Congress saw the official launch of a new project to create a Community of Practice for consultant and advanced practitioner biomedical scientists, and the project is looking for input to help guide its development.

Menarini has added Coyote FlashDetect PCR to its range of diagnostic solutions. These scalable rapid PCR devices will enable users to gain high quality results within 35 minutes.

Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, recently demonstrated the clinical impact of using its flagship metagenomic pathogen detection test, Delve Detect, to diagnose culture-negative and co-infections in the central nervous system.

Scottish Brain Sciences (SBS), a leading clinical research organisation dedicated to transforming the early detection and treatment of Alzheimer’s disease and other neurodegenerative conditions, has opened a new state-of-the-art clinical research centre at ONE BioHub, Aberdeen.

Thermo Fisher Scientific has announced 510(k) clearance of the EXENT Analyser and Immunoglobulin Isotypes (GAM) Assay, a first-of-its-kind automated platform for clinical laboratories.

Hologic has announced that its Genius Digital Diagnostics System achieved expanded CE marking in the European Union and is now approved to image and review both cell and tissue specimens.

Launch Diagnostics has announced a new distribution deal with Biocare Medical for its extensive range of IHC antibodies and reagents, plus associated automated solutions.

A landmark international study led by the Medicines and Healthcare products Regulatory Authority (MHRA) has exposed significant variability in microbiome research methods across the world, highlighting an urgent need to adopt unified standards for the global harmonisation of gut microbiome research.

A simple blood test for platelet activity at middle age could one day help identify people at risk for Alzheimer’s disease decades ahead of time, allowing for possible preventive therapy.

QIAGEN has launched QIAsymphony Connect, the next generation of its widely adopted automated nucleic acid purification platform, at the 2025 AMP (Association for Molecular Pathology) annual meeting.

AI-powered virtual staining innovator Pictor Labs has announced the launch of ClearStain, its latest advancement designed to revolutionise molecular diagnostic workflows.

A research team from Trinity College Dublin has unveiled a groundbreaking new approach to vaccination that could redefine how we protect against respiratory infections.

Randox Toxicology has launched its first nitazenes array – a pioneering immunoassay designed to detect a broad spectrum of nitazene analogues with speed, accuracy, and clinical relevance.

New evaluation of NHS England’s emergency department opt-out testing has identified thousands of people living unknowingly with bloodborne viruses.

The Institute of Biomedical Science (IBMS), The Royal College of Pathologists (RCPath) and the Association for Laboratory Medicine (LabMed) have released a joint statement announcing a temporary pause in national quality assurance panel activities while a sustainable model is developed.

Clinical trial data demonstrate how Bio-Techne's spatial biology technology and Nucleai's AI-powered multi-modal platforms can identify predictive biomarkers in immunotherapy and targeted therapy-treated melanoma patients.

A new policy paper published by the Medicines and Healthcare products Regulatory Agency (MHRA) commits the UK to major reform in treatments for rare diseases, with a new rulebook for rare therapies being prepared for publication next year.